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Abstract
Background: HDL cholesterol (HDL-C) is an established marker of cardiovascular risk with significant genetic determination.
However, HDL particles are not homogenous, and refined HDL phenotyping may improve insight into regulation of HDL
metabolism. We therefore assessed HDL particles by NMR spectroscopy and conducted a large-scale candidate gene
association analysis.
Methodology/Principal Findings: We measured plasma HDL-C and determined mean HDL particle size and particle number
by NMR spectroscopy in 2024 individuals from 512 British Caucasian families. Genotypes were 49,094 SNPs in .2,100
cardiometabolic candidate genes/loci as represented on the HumanCVD BeadChip version 2. False discovery rates (FDR)
were calculated to account for multiple testing. Analyses on classical HDL-C revealed significant associations (FDR,0.05)
only for CETP (cholesteryl ester transfer protein; lead SNP rs3764261: p=5.6*10
215) and SGCD (sarcoglycan delta; rs6877118:
p=8.6*10
26). In contrast, analysis with HDL mean particle size yielded additional associations in LIPC (hepatic lipase;
rs261332: p=6.1*10
29), PLTP (phospholipid transfer protein, rs4810479: p=1.7*10
28) and FBLN5 (fibulin-5; rs2246416:
p=6.2*10
26). The associations of SGCD and Fibulin-5 with HDL particle size could not be replicated in PROCARDIS
(n=3,078) and/or the Women’s Genome Health Study (n=23,170).
Conclusions: We show that refined HDL phenotyping by NMR spectroscopy can detect known genes of HDL metabolism
better than analyses on HDL-C.
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Introduction
HDL cholesterol (HDL-C) is an established marker of
cardiovascular risk. It reflects reverse cholesterol transport
(RCT) and higher plasma HDL-C is associated with lower
cardiovascular risk. However, the cholesterol content of HDL
particles is mainly a historically founded and analytically feasible
surrogate of RCT and is it not clear whether HDL-C is indeed the
best RCT-related cardiovascular risk marker [1,2,3,4,5]. HDL
particles are not a homogenous class but can be further divided
into subclasses. Most studies suggest that large HDL particles are
associated with a favourable outcome, while small HDL particles
may even be positively correlated with CV risk [1,5,6].
Correspondingly, the lipid disturbances of the metabolic syn-
drome include a decreased mean HDL particle size [3,7].
Although HDL subclass measurements have been widely used
for scientific purposes, practical clinical application is not well
established yet, and there is an ongoing debate on whether lipid
subclass measurements should be implemented into clinical
routine [4,5,8].
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features is not completely understood, but a strong genetic
influence has been shown [9,10]. Recently, genome-wide
association (GWA) studies have identified several loci that affect
HDL-C [11,12,13]. However, only a small proportion of the
heritability of HDL-C is explained by these loci. We hypothesized
that a genetic analysis of distinct HDL particle traits may provide
greater sensitivity and broaden our understanding of the genetic
regulation of HDL metabolism. Accordingly, we conducted a
large-scale candidate gene analysis on HDL particle traits. We
genotyped 49,094 single nucleotide polymorphisms (SNPs) in
.2,100 cardiometabolic candidate genes and assessed mean HDL
particle size and HDL particle number by NMR spectroscopy.
Methods
Ethics Statement
The study was approved by the Leicestershire Research Ethics
Committee, and all subjects provided written informed consent.
The study conforms with the principles outlined in the Declaration
of Helsinki, and all procedures followed were in accordance with
institutional guidelines.
Subjects
Analyses were carried out in the GRAPHIC (Genetic
Regulation of Arterial Pressure of Humans in the Community)
cohort that has been previously described in detail [14]. In short,
GRAPHIC contains 2,037 white European subjects in 520 nuclear
families from the general population. Families were recruited by
writing to women aged 40 to 69 registered with participating
family practitioners in Leicestershire, UK, inviting them and their
family to take part. Families were included if both parents aged 40
to 60 years and 2 offspring .18 years wished to participate. Study
subjects had a detailed history taken and were examined by
research nurses following standard operating procedures. Mea-
surements included height, weight, waist-hip ratio and clinic and
ambulatory blood pressure. Non-fasting blood samples were
obtained for laboratory analysis.
Lipid Phenotyping
HDL-C was determined enzymatically using the standard
CHOD/PAP assay in an Olympus AU5430 analyser. GRAPHIC
blood samples for NMR spectroscopy were stored at –80uC and
kept unthawed until the day of NMR measurements. HDL
particle size and number were determined by NMR spectroscopy
at LipoFIT Analytic GmbH (Regensburg, Germany) as previously
described [9]. In short, gradient weighted NMR spectra of blood
plasma were recorded, which lead to characteristic overall profiles
of the lipoprotein signals. Using the gradient weighted spectra,
spectral regions ranging from 1.5 to 0.7 ppm were modeled into a
set of 15 lipoprotein subclasses, in particular 4 HDL subclasses.
Mean HDL particle size and HDL particle number were then
computed from the distribution of the 4 HDL subclasses. For
validation we also reconstructed HDL-C from NMR data.
Genotyping
Genotyping was carried out using the HumanCVD BeadChip
version 2 (Illumina Inc, CA) [15] based on the Infinium II
genotyping platform (Illumina). Briefly, the HumanCVD Bead-
Chip contains 49,094 SNPs in .2,100 cardiovascular candidate
genes. The selection process of candidate genes and SNPs was led
by investigators from the Institute of Translational Medicine and
Therapeutics (ITMAT) of the University of Pennsylvania, the
Broad Institute and by the National Heart Lung Institute (NHBLI)
supported Candidate-gene Association resource (CARe). Genes
were prioritized in three groups: [1] genes and loci with a high
likelihood of functional cardiovascular significance were captured
with an r
2$0.8 for HapMap SNPs with MAF.0.02 (Tier 1). [2]
Loci that are potentially involved in cardiovascular phenotypes
were covered with r
2$0.5 for MAF .0.05 (Tier 2). [3] For mainly
larger genes of lower interest only non-synonymous and known
functional variants with MAF .0.01 were captured (Tier 3).
Additionally, the array contains SNPs informative of ancestry or of
copy number variations as well as duplicates for quality control.
Statistical analyses
Genotypes were carefully checked before association analyses.
We excluded SNPs that represent ancestry or copy number
variations, sex chromosomal SNPs and duplicates. We then
applied the following filters for exclusion: missingness rate .10%
(reflecting poor genotyping quality); deviation from Hardy-
Weinberg equilibrium (p,0.0001) in the parental generation;
minor allele frequency ,0.01; and .10 Mendelian inconsistencies
(also reflecting poor genotyping quality given the known familial
structure in GRAPHIC).
Heritabilities of HDL-C, HDL particle size and particle number
were estimated using the Sequential Oligogenic Linkage Analysis
Routines (SOLAR v2.0) software[16]. In brief, total phenotypic
variance of each trait was partitioned into genetic and environ-
mental components. The mixed model applied to the data
incorporated fixed effects for known covariates (age, age
2 and
sex), and variant components were calculated for genetic and
residual environmental effects. The estimates were modelled to
best fit the observed data using maximum likelihood approach.
The total genetic component was partitioned into polygenic
additive effect (narrow sense heritability) and non-additive
(dominant) allelic effects.
Association analyses were carried out using generalized
estimating equations (GEE) with an exchangeable correlation
structure to account for the shared genetic background in families.
All analyses were adjusted for gender, age and age
2 (to account for
the two generation structure of GRAPHIC). Calculations were
performed in STATA (STATA Corp., Texas). Manhattan and LD
plots were constructed using the Haploview program [17], gene
centered association plots were drawn using the Locusview software
(T. Petryshen, A. Kirby, M. Ainscow, available at www.broad-
institute.org/science/programs/medical-and-population-genetics/
locusview20).
To address the problem of multiple testing we calculated false
discovery rates (FDR). FDR describes the number of expected
false positives among all positive findings at a certain p-value
threshold [18]. We accepted an FDR of #0.05 as experiment-wide
significant. FDR (expressed as q-values) were calculated using the
R-based q-value tool applying the bootstrap algorithm [19].
Replication analyses
In silico replication analyses were carried out in 23,170 women
(mean age 54.2 years) of the Women Genome Health Study
(WGHS) and 3,078 individuals (69.8% males and mean age 62.7
years) of the PROCARDIS cohort. The studies have been
previously described in detail [20,21]. In both studies, NMR
measurements were performed using the Lipoprofile-II assay
(Liposcience, Raleigh, NC). Genotypes in WGHS were imputed
from GWA data based on the HumanHap300 Duo "+" chips or a
combination of the HumanHuman300 Duo and iSelect chips
(Illumina, San Diego, CA) with the Infinium II protocol [20]. In
PROCARDIS genotypes where based on the HumanCVD bead
chip (Illumina, San Diego, CA) [21].
Genetics of HDL Particles
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e14529Results
Subjects
Genotypes, plasma HDL-C and NMR HDL particle traits were
available on 2024 GRAPHIC subjects. The characteristics of these
subjects, partitioned by generation and gender are shown in
Table 1. The values are typical of a sample of the general
population in the UK indicating the representativeness of the
GRAPHIC subjects. A few subjects (37) were taking lipid lowering
therapy (mainly statins).
HDL traits
The distributions of HDL particle size and HDL particle
number in the GRAPHIC subjects are shown in Figures S1 and
S2. Both traits showed nearly normal distribution. Correlation
between (enzymatically determined) HDL-C and mean HDL
particle size was 0.67, between HDL-C and HDL particle number
0.41; no correlation was present between HDL particle size and
HDL particle number. For validation we also reconstructed HDL-
C from NMR data. These computed HDL-C values showed good
agreement with enzymatically determined HDL-C (Figure S3).
Narrow-sense heritability estimates gave values of 0.5260.07
(r
26SE; p=3.2*10
241), 0.3560.04 (p=8.0*10
220) and
0.4460.04 (p=10
226) for HDL-C, HDL particle number and
mean HDL particle size, respectively.
Genetic analysis
Of the 49,094 SNPs represented on the HumanCVD chip,
1,775 were excluded because they belonged to admixture and
ancestry informative control markers (AIMs) and 106 because they
were either duplicate SNPs or copy number variants. 12,443 SNPs
were removed as their minor allele frequency was ,0.01, 20 SNPs
due to Mendelian errors, 424 - due to low genotyping call rate and
107 SNPs because of Hardy-Weinberg equilibrium violation.
Finally, we excluded 638 SNPs on sex chromosomes and 4 SNPs
due to lack of unambiguous rs identification number, leaving
33,577 SNPs for the association analyses.
For the purpose of validation and comparison with recent GWA
studies, we first examined association of the SNPs with HDL-C as
routinely assessed by enzymatic assay. The genomic control
coefficient (l) showed no evidence for inflation for HDL-C
(l=0.966). The distribution of association signals for HDL-C is
shown in Figure 1A, and lead SNPs for loci showing experiment-
wide significance (i.e. FDR q#0.05) in Table 2. As expected from
physiology and consistent with recent GWA studies [12], the
CETP gene (encoding cholesteryl ester transfer protein) showed
the strongest signal (lead SNP rs3764261, p=5.6*10
215,
q=9.7*10
211). A significant association was also found for the
SGCD gene encoding sarcoglycan delta (lead SNP rs6877118,
p=8.6*10
26, q=0.012). More detailed descriptions of the
association signals at the CETP and SGCD loci with HDL-C
are shown in Figure 2 A/B. SNPs in several other genes showed
significant P values fo HDL-C; lead SNPs for the top 10 genes are
shown in Table S1. However, besides CETP and SGCD no other
gene reached experiment-wide significance for HDL-C, taking
into account the number of SNPs tested.
We next examined the associations with mean HDL particle
size (Figure 1B, Table 2 and Table S2) as retrieved from
NMR spectroscopy. Genomic inflation factor l was 0.949 for
HDL particle size. Again polymorphisms in the CETP gene
showed the most significant association (lead SNP rs17231506,
p=1.9*10
210, q=3.7*10
26)( Figure 2A). The second strongest
association was again found for SGCD (lead SNP rs10071215,
p=3.5610
29, q=3.8*10
25; Figures 1B and 2B). The lowest p-
value for HDL particle size in both these genes was seen with a
different SNP to that for HDL-C (Table 2). However, in both
instances the relevant SNPs were in strong LD with each other
(Figures 2A and 2B), suggesting that these are mapping the same
signals. Besides CETP and SGCD, association analysis of HDL
particle size revealed experiment-wide significant associations in
three further genes (Figure 1B): LIPC (encoding hepatic lipase,
lead SNP rs261332, p=6.1*10
29, q=3.9*10
25), PLTP (encoding
phospholipid transfer protein, lead SNP rs4810479: p=1.7*10
28,
q=6.0*10
25) and FBLN5 (encoding fibulin-5, lead SNP
rs2246416, p=6.2*10
26, q=0.007) (Table 2). More detailed
information of the location of the association signals in these genes
and the LD between SNPs are shown in Figures 2C, 2D and
2E, respectively.
The association analysis with NMR-derived HDL particle
number did not yield experiment-wide significant results
(Figure 1C). The ten genes with the strongest association results
for particle number are shown in Table S3.
We next analysed two top SNPs for each of our two novel
suggestive loci (SGCD: rs10071215 and rs6877118; Fibulin-5:
Table 1. Relevant characteristics of the GRAPHIC subjects partitioned by generation and gender.
Fathers Mothers Sons Daughters
Variable (n=512) (n=512) (n=509) (n=491)
Age (years) 53.8 (4.3) 51.8 (4.4) 25.0 (5.1) 25.93 (5.4)
Body mass index (kg/m2) 27.8 (4.0) 27.1 (4.5) 24.9 (4.1) 24.6 (5.0)
Mean 24-hour SBP (mmHg) 124.3 (11.5) 117.0 (11.5) 120.8 (8.1) 112.8 (7.2)
Mean 24-hour DBP (mmHg) 77.7 (7.2) 71.7 (7.6) 69.2 (6.5) 67.9 (5.2)
Total Cholesterol (mmol/L) 5.58 (0.99) 5.68 (0.98) 4.52 (0.89) 4.50 (0.82)
LDL Cholesterol (mmol/L) 3.25 (0.7) 3.26 (2.52) 2.52 (0.68) 2.50 (0.59)
HDL Cholesterol (mmol/L) 1.30 (0.3) 1.62 (0.38) 1.31 (0.27) 1.47 (0.34)
HDL particle number (nmol/L) 25,805 (3568) 25,688 (3341) 25,885 (3664) 25,752 (3497)
Mean HDL particle size (nm) 8.19 (0.25) 8.19 (0.24) 8.19 (0.25) 8.20 (0.26)
Lipid lowering therapy n (%) 25 (4.9) 11 (2.2) 0 1 (0.2%)
Data are means and standard deviations or counts and percentages.
doi:10.1371/journal.pone.0014529.t001
Genetics of HDL Particles
PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e14529rs2246416 and rs3783937), in two independent cohorts: the
Women’s Genome Health Study (WGHS) and the PROCARDIS
cohort [20,21]. In WGHS, the two SGCD SNPs were not
imputable due to low minor allele frequency. In PROCARDIS the
two SCGD SNPs were directly genotyped and showed no
association with mean HDL particle size (Table S4). The two
Fibulin-5 SNPs were not associated with HDL particle size in
either WGHS or PROCARDIS (Table S4).
Figure 1. Summary of association results for HDL-C, HDL particle size and HDL particle number. Data are –log transformed p-values from
association analyses for all SNPs plotted against their chromosomal location, for enzymatically determined HDL-C (panel A), NMR-derived mean HDL
particle size (panel B) and NMR-derived HDL particle number (panel C). All signals with experiment-wide significance are labelled.
doi:10.1371/journal.pone.0014529.g001
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We measured HDL subclass distribution by NMR spectroscopy
in .500 families of the GRAPHIC cohort. The calculated
heritability of mean HDL particle size (,44%) in the GRAPHIC
study is in line with the literature (,28–52%), while that of HDL
particle number (,35%) is somewhat lower than previously
reported (48–65%) [9,22]. Conducting a large-scale candidate
gene association analysis with mean HDL particle size and HDL
particle number, we found that the analysis of HDL particle size
detected genes known to be involved in HDL metabolism better
than the equally powered scan on enzymatically determined HDL-
C. We found significant association of Fibulin-5 and SGCD
polymorphisms with HDL particle size, but were not able to
replicate these findings in additional cohorts.
From a mechanistic point of view, HDL cholesterol level is
determined by two factors: first the number of circulating HDL
particles, and second the mean cholesterol content per particle, i.e.
its size or subclass distribution. It is likely that these two variables
are regulated by distinct biological mechanisms. Given the
increasingly compelling evidence that cardiovascular risk related
to HDL-C is mediated by specific features of HDL particles,
understanding the genetic regulation of these features and also
which features are affected by loci associated with HDL-C has
important clinical relevance. HDL subclasses and particle number
can be assessed by several techniques. Ultracentrifugation, gel
electrophoresis, precipitation and immunological assays are
established methods to separate HDL particles into subfractions.
More recently, NMR spectroscopy has become increasingly used
for determining lipid subfractions [5,9,23].
The proof of principle for our hypothesis that refined HDL
phenotyping would provide increased sensitivity in detecting loci
affecting HDL metabolism compared with HDL-C is illustrated by
the findings for PLTP and LIPC. Both proteins are associated with
HDL metabolism. PLTP transfers phospholipids from triglyceride-
rich lipoproteins (VLDL) to HDL particles while hepatic lipase
hydrolyses triglycerides and phospholipids and also facilitates
receptor binding of lipoprotein particles [24]. These functions may
explain the stronger association of variants observed in these genes
with HDL particle size (which will be influenced by their
triglyceride/phospholipid content) than with HDL cholesterol.
Furthermore, although the C allele of lead SNP rs4810479 is
associated with an increased mean particle size, it is at the same
time associated with decreased particle number albeit not at an
experiment-wide level of significance (p=0.002; q=0.71). As a
result, the association with HDL cholesterol is markedly weakened
(p=0.014) (Table S2). While variants in both genes have now
been associated with HDL-C, it is notable that for PLTP a meta-
analysis of over 19.000 individuals was required for the signal to
reach genome-wide significance [12]. This again demonstrates the
advantages of distinct HDL particle phenotyping. During the
preparation of this manuscript, Chasman et al. published a large
genome-wide association study for NMR-based lipid traits [20],
and found similar associations between HDL particle size and
polymorphisms in CETP, LIPC and PLTP. The totality of the
evidence for these loci therefore indicates that their effect on HDL-
C is primarily mediated by their impact on HDL particle size.
We observed potentially novel associations with HDL particle
size of variants in the sarcoglycan delta coding gene (SGCD) and
in the fibulin-5 gene (FBLN5). The signal in SCGD is based on
four SNPs (rs6869314, rs10071215, rs6877118, rs10491465)
which all have very low minor allele frequencies (0.010–0.014)
and are in high LD (pairwise r
2 0.6-0.9). SCGD protein has been
associated with development of cardiomyopathies [25]. There is
no pre-existing evidence for its involvement in lipid metabolism.
Given the low allele frequencies, the signal is based on rougly 40
heterozygous individuals. Given that no association was seen in
PROCARDIS, we have to conclude that this finding is likely to be
false positive.
In contrast to the association in SCGD, that in FBLN5 was
based on 798 heterozygous and 176 homozygous individuals for
the minor allele. Furthermore, of 18 SNPs analysed in the FBLN5
gene, 9 show a nominal significant association with HDL particle
size (Figure 2E). Fibulin-5 (syn. ARMD3, DANCE) is an
extracellular matrix protein that has been implicated in vascular
Table 2. Significant association results for HDL cholesterol and HDL particle size.
HDL cholesterol
lead SNP Gene Transcript chr.
major/minor
allele MAF beta ± SE (mmol/l) P-value q-value
rs3764261 CETP cholesteryl ester transfer
protein
16 G/T 0.32 0.0960.01 5.63*10
215 9.7*10
211
rs6877118 SGCD sarcoglycan delta 5 G/A 0.01 20.1260.03 8.59*10
26 0.012
mean HDL particle size
lead SNP gene Transcript chr.
major/minor
allele MAF beta ± SE (nm) p-value q-value
rs17231506 CETP cholesteryl ester transfer
protein
16 C/T 0.32 0.05160.008 1.94*10
210 3.7*10
26
rs6869314 SGCD sarcoglycan delta 5 T/G 0.01 20.1360.021 3.51*10
29 3.8*10
25
rs261332 LIPC hepatic lipase 15 G/A 0.20 0.05960.010 6.13*10
29 3.9*10
25
rs4810479 PLTP phospholipid transfer
protein
20 T/C 0.27 20.04860.009 1.67*10
28 6.0*10
25
rs2246416 FBLN5 fibulin-5 14 A/G 0.29 0.04060.009 6.22 * 10
26 0.0070
Lead SNPs of genes with experiment-wide significant (q,0.05) association tests. Results are from GEE regression analyses adjusted for age, age
2 and gender. SNP, single
nucleotide polymorpism; chr., chromosome; MAF, minor allele frequency in the parental generation; Beta, beta coefficient per minor allele copy; SE; standard error. A
negative beta coefficient indicates a lower value for the trait for each copy of the minor allele.
doi:10.1371/journal.pone.0014529.t002
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and organization of elastic fibers [27] (DANCE: developmental
arteries and neural crest EGF-like protein). Mutations have been
associated with recessive cutis laxa and age-related macular
degeneration (ARMD) [28,29]. The association of FBLN5 with
ARMD is particularly interesting, because this condition is defined
by the deposition of cholesterol containing drusen, an obvious
parallel with atherosclerotic lesions [30]. ARMD has been
consistently associated with apoE polymorphisms and HDL
particle traits, providing further evidence for a role of reverse
cholesterol transport in this condition [31,32]. Moreover, fibulin-5
is upregulated in atherosclerotic and ballon-injured vessel wall
[33]. Hence, one possible explanation of the association between
FBLN5 polymorphisms and HDL particle size is the affection of
cholesterol flux to HDL particles in the vessel wall. Fibulin-5 has
furthermore been shown to bind superoxide dismutase (SOD)
[34]. As oxidative stress affects HDL subclass distribution [35], an
alternative explanation would be an effect of FBLN5 polymor-
phisms on SOD activity in the vessel wall and hence an altered
oxidative state. However, we were not able to replicate association
between Fibulin-5 polymorphisms and HDL particle size in two
independent cohorts, and hence the significance of our finding in
GRAPHIC remains doubtful.
Interestingly, we did not observe any experiment-wide signif-
icant associations with HDL particle number. The negative
finding may be explained by the fact that HDL particle number
has a somewhat weaker heritability (h
2=0.35) than HDL
cholesterol and mean HDL particle size (h
2=0.52 and h
2=0.44,
respectively). Another possible explanation is that the genes
regulating particle number may not be represented on the
HumanCVD BeadChip. This possibility is supported by the fact
that the HumanCVD BeadChip chip contains candidate genes
mainly based on classical cardiometabolic traits. However, HDL
cholesterol is much more determined by mean cholesterol content
per particle than by particle number. In our data, NMR-derived
HDL mean particle size explains 45% of the variance of
enzymatically determined HDL cholesterol, while HDL particle
number accounts for only 17% of HDL-C variance. Hence, genes
controlling HDL particle number are difficult to discover using
traditional lipid phenotyping. Therefore, genes affecting HDL
particle number may be underrepresented on the HumanCVD
BeadChip. However, at least two out of the top ten loci where we
found associations with HDL particle number (Table S3) have
previously been implicated in lipid traits: HNF4a (encoding
hepatocyte nuclear factor a; lead SNP rs3212197, p=0.00028,
q=0.64) is a known MODY (mature onset diabetes of the young)
gene that has been associated with HDL cholesterol and apoA1 in
recent GWAS [20,36], while TRIB1 (tribbles homolog 1; lead
SNP rs4871598, p=0.00030, q=0.64) has been correlated with
triglyceride levels in the same studies.
Limitations
Some limitations of our study should be noted. First, although
large-scale, our study was nonetheless a candidate gene analysis.
The HumanCVD BeadChip array specifically targets known
genes/loci involved or suspected to be involved in HDL
metabolism including those from available GWAS studies, but is
limited in its ability to discover hitherto completely unsuspected
genes. Also, our blood samples were taken from non-fasting
individuals which could impact on lipid measurements. However,
recent data suggest that the differences between fasting and non-
fasting state are small with respect to HDL particle features [20].
Given that meta-analyses of several tens of thousands of subjects
have been required to robustly detect some of the genetic variants
affecting HDL cholesterol, an important limitation of the study is
power. This together with the limited sampling of the genome
undoubtedly means that many loci that affect HDL-C and HDL
particle features have not been detected. However, our principle
objective was to compare genetic association signals seen for HDL-
C and that for HDL particle features in the same population and
obtain some novel mechanistic insights related to some of the
associations affecting HDL metabolism. In this regard, the nuclear
family study design limited the impact of any population structure
and the fact that the GRAPHIC cohort is representative of the
general European Caucasian population means that our findings
are generalisable, at least to this population.
Conclusion
We present a large-scale candidate gene analyses on NMR-
derived HDL particle traits in over 2,000 individuals. We show
that refined HDL phenotyping can detect known genes of HDL
metabolism better than analyses on enzymatically determined
HDL-C and may broaden understanding of HDL biology.
Supporting Information
Figure S1 Distribution of mean HDL particle size in the
GRAPHIC cohort. Brown bars: Density histogram of mean HDL
particle size in the GRAPHIC cohort. Continuous line: normal
distribution.
Found at: doi:10.1371/journal.pone.0014529.s001 (0.60 MB TIF)
Figure S2 Distribution of HDL particle number in the
GRAPHIC cohort. Brown bars: Density histogram of mean
HDL particle size in the GRAPHIC cohort. Continuous line:
normal distribution.
Found at: doi:10.1371/journal.pone.0014529.s002 (0.64 MB TIF)
Figure S3 Correlation of HDL cholesterol determined enzy-
matically with HDL cholesterol computed from NMR-derived
HDL subclass data.
Found at: doi:10.1371/journal.pone.0014529.s003 (0.28 MB TIF)
Table S1 Lead SNPs for 10 genes with the strongest association
results for enzymatically determined HDL-C. Results are from
GEE regression analyses adjusted for age, age
2
and gender. The
right part of the table shows association results of the SNPs with
the other two measured traits’ mean HDL particle size and HDL
particle number. Chr.: chromosome; MAF: minor allele frequen-
cy; beta: beta coefficient per minor allele copy; SE: standard error.
A negative beta coefficient indicates a lower value for the trait for
each copy of the minor allele. Gene abbreviations: CETP:
cholesteryl ester transfer protein; SGCD: sarcoglycan delta;
CACNA1C: voltage dependent calcium channel L type alpha
Figure 2. Association signals and LD structure of loci associated with HDL traits. Panel A: CETP (cholesterol ester transfer protein) gene;
panel B: SGCD (sarcoglycan delta) gene; panel C: PLTP (phospholipid transer protein) gene; panel D: LIPC (hepatic lipase) gene; panel E: FBLN5
(fibulin-5) gene. In each panel, data in the upper part are –log transformed p-values from association analyses with HDL mean particle size and HDL
cholesterol, adjusted for age, age
2 and gender (open circles: p.0.01, solid circles: p#0.01; pval – p-value). The lower part shows linkage
disequilibrium (LD) structure of genotyped SNPs in the GRAPHIC cohort (r
2-based grey shading; white: no LD (r
2=0), black: complete LD (r
2=1)). For
legibility, in panel D (LIPC) only SNPs with significant association with mean HDL particle size (p,0.05) were plotted.
doi:10.1371/journal.pone.0014529.g002
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TNNI3K: TNNI3 interacting kinase; ABCB11: ATP-binding
cassette subfamily B member 11; SLC12A3: solute carrier family
12 member 3; FBLN5: fibulin 5; FOXP1: forkhead box P1;
CAV3: caveolin 3.
Found at: doi:10.1371/journal.pone.0014529.s004 (0.03 MB
DOC)
Table S2 Lead SNPs for 10 genes with the strongest association
results for mean HDL particle size. Results are from GEE
regression analyses adjusted for age, age
2
and gender. The right
part of the table shows association results of the SNPs with the
other two measured traits’ mean HDL cholesterol and HDL
particle number. Chr.: chromosome; MAF: minor allele frequen-
cy; beta: beta coefficient per minor allele copy; SE: standard error.
A negative beta coefficient indicates a lower value for the trait for
each copy of the minor allele. Gene abbreviations: CETP:
cholesteryl ester transfer protein; SGCD: sarcoglycan delta; LIPC:
hepatic lipase; PLTP: phospholipid transfer protein; FBLN5:
fibulin 5; SLC22A2: solute carrier family 22 member 2; SMPD4:
neutral sphingomyelinase-3; HSPA8: heat shock 70 kDa protein 8;
CHUK: conserved helix-loop-helix ubiquitous kinase; TNIP3:
TNFAIP3 interacting protein.
Found at: doi:10.1371/journal.pone.0014529.s005 (0.03 MB
DOC)
Table S3 Lead SNPs for 10 genes with the strongest association
results for HDL particle number. Results are from GEE regression
analyses adjusted for age, age
2 and gender. The right part of the
table shows association results of the SNPs with the other two
measured traits’ HDL cholesterol and mean HDL particle size.
Chr.: chromosome; MAF: minor allele frequency; beta: beta
coefficient per minor allele copy; SE: standard error. A negative
beta coefficient indicates a lower value for the trait for each copy
of the minor allele. Gene abbreviations: TGFB3: transforming
growth factor beta 3; PROS1: protein S alpha; ABCA4: ATP-
binding cassette subfamily A member 4; KCNJ2: potassium
inwardly rectifying channel subfamily J member 2; CNTF: ciliary
neurotrophic factor; STARD13: START domain containing 13;
IL4: interleukin 4; EGFR: epidermal growth factor receptor;
HNF4A: hepatocyte nuclear factor 4 alpha; TRIB1: tribbles
homolog 1.
Found at: doi:10.1371/journal.pone.0014529.s006 (0.03 MB
DOC)
Table S4 Replication analyses in WGHS and PROCARDIS.
SGCD SNPs in WGHS were not imputable due to low minor
allele frequency. Beta-coefficients are given per copy of minor
allele, assuming an additive model of inheritance, adjusted for age
(and gender in PROCARDIS). rsq: imputation quality measure;
MAF: minor allele frequency * Due to low MAF, homozygous and
heterozygous carriers of the minor allele were pooled, hence the
beta-coefficient is given for the presence of the minor allele.
Found at: doi:10.1371/journal.pone.0014529.s007 (0.03 MB
DOC)
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